Patents by Inventor Bradley Henkle

Bradley Henkle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20230381308
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: March 28, 2023
    Publication date: November 30, 2023
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20230192835
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: September 9, 2022
    Publication date: June 22, 2023
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Optimized anti-TL1A antibodies
    Patent number: 11440954
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20220259320
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 28, 2022
    Publication date: August 18, 2022
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
    Patent number: 11292848
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 5, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20210093718
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: November 23, 2020
    Publication date: April 1, 2021
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20190247498
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: April 15, 2019
    Publication date: August 15, 2019
    Inventors: Janine Bilsborough, Stephan R. Targan, Bradley Henkle
  • Neutralizing anti-TL1A monoclonal antibodies
    Patent number: 10322174
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: June 18, 2019
    Assignee: Cedars-Sinai Medical Center
    Inventors: Janine Bilsborough, Stephan Targan, Bradley Henkle
  • NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
    Publication number: 20180110855
    Abstract: Described herein are methods and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), Crohn's Disease (CD), ulcerative colitis (UC) and medically refractive-ulcerative colitis (MR-UC). In particular, disclosed are anti-TL1A antibodies useful for the treatment of IBD.
    Type: Application
    Filed: October 24, 2017
    Publication date: April 26, 2018
    Inventors: Janine Bilsborough, Stephan Targan, Bradley Henkle